ULTRA-TECHNEKOW V4
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ULTRA-TECHNEKOW V4 (ULTRA-TECHNEKOW V4).
ULTRA-TECHNEKOW V4 is a radiopharmaceutical containing sodium pertechnetate Tc-99m. Technetium-99m is a gamma-emitting radionuclide that localizes in specific tissues due to its physical and chemical properties. In the brain, it crosses the blood-brain barrier only in areas with disrupted integrity (e.g., tumors, infarcts). In the thyroid, it is trapped similarly to iodide but not organified. It is secreted into the gastric mucosa and excreted via the renal system. Its distribution allows for scintigraphic imaging of various organs.
| Metabolism | Technetium-99m is not metabolized; it remains as pertechnetate ion until physical decay to technetium-99 (half-life ~6 hours). Excretion is primarily renal via glomerular filtration, with some gastrointestinal secretion. |
| Excretion | Primarily renal excretion: 90-95% of the administered technetium-99m is excreted unchanged via glomerular filtration within 24 hours. Less than 5% is eliminated via fecal route. |
| Half-life | Physical half-life of technetium-99m is 6.02 hours; biological half-life is approximately 24 hours, resulting in effective half-life of 5.2 hours. Clinical imaging is typically performed within 30 minutes to 4 hours post-injection. |
| Protein binding | Negligible protein binding (<5%). Primarily bound to albumin. |
| Volume of Distribution | Vd = 0.5-0.8 L/kg, indicating distribution into extracellular fluid and total body water, with minimal intracellular penetration. |
| Bioavailability | Intravenous: 100% bioavailable. Not administered orally. |
| Onset of Action | Intravenous: Localization in target organs begins within minutes; optimal imaging time is 30-60 minutes for most studies (e.g., bone, cardiac). |
| Duration of Action | Activity sufficient for imaging persists for 4-6 hours post-injection. By 24 hours, less than 5% of initial activity remains. |
| Molecular Weight | 163.0 (as NaTcO4, including Tc-99m; exact value varies with isotope) |
Intravenous administration of 5-30 mCi (185-1110 MBq) for imaging, as a single dose.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required; however, caution in severe renal impairment due to potential altered biodistribution. |
| Liver impairment | No specific dose adjustment recommended; however, monitor for altered clearance in severe hepatic impairment. |
| Pediatric use | Weight-based: 0.05-0.15 mCi/kg (1.85-5.55 MBq/kg) intravenously; minimum dose 1 mCi (37 MBq). |
| Geriatric use | No specific dose adjustment; use lowest effective dose based on clinical status and renal function. |
| 1st trimester | Technetium-99m pertechnetate crosses the placenta. Use only if clearly needed; consider radiation dose to fetus. |
| 2nd trimester | Use only if clearly needed; fetal thyroid uptake begins at 12 weeks, risking thyroid ablation. |
| 3rd trimester | Use only if clearly needed; fetal thyroid uptake risk persists. Minimize radiation exposure. |
Clinical note
Comprehensive clinical and safety monograph for ULTRA-TECHNEKOW V4 (ULTRA-TECHNEKOW V4).
| Placental transfer | Technetium-99m pertechnetate crosses the placenta readily; fetal thyroid uptake can occur after 12 weeks gestation, potentially causing thyroid dysfunction. |
| Breastfeeding | Breastfeeding should be interrupted for 24-48 hours after administration. Express and discard milk during this period. Resume feeding when radioactivity in milk is negligible. |
■ FDA Black Box Warning
None
| Serious Effects |
Known hypersensitivity to technetium-99m pertechnetate or any component of the formulation
| Precautions | Hypersensitivity/anaphylactoid reactions: Rare but risk, Radiation exposure: Must justify benefit vs. cumulative radiation dose; use minimal activity for adequate imaging, Breastfeeding: Interrupt for at least 24 hours after administration, Pregnancy: Consider alternatives unless imaging is essential (fetal radiation exposure), Children: Adjust dose based on weight and minimize activity, Thyroid uptake: Ensure patient is not taking medications that interfere with uptake (e.g., thyroid hormones, antithyroid drugs, perchlorate); perform image promptly after injection, Radiopharmaceutical should be used within specified time after preparation (elution) to avoid excessive free pertechnetate |
| Food/Dietary | No known food interactions. No dietary restrictions required. Maintain adequate hydration to promote renal excretion of Tc-99m pertechnetate. |
Loading safety data…
| Lactation Rating | L4 (Hazardous) |
| Teratogenic Risk | Technetium-99m pertechnetate crosses the placenta. First trimester: risk of fetal thyroid ablation due to iodine uptake; avoid unless essential. Second/third trimester: fetal radiation exposure; use only if benefit outweighs risk. No known structural teratogenicity. |
| Fetal Monitoring | Monitor maternal vital signs during and after injection. Fetal radiation dose assessment via dosimetry if administration is necessary. Ensure adequate maternal hydration to promote radionuclide excretion. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies not available; theoretical risk from radiation to gonads considered minimal at diagnostic doses. |
| Clinical Pearls | Ultra-TechneKow V4 is a technetium-99m generator that elutes sodium pertechnetate Tc-99m. Ensure eluate is used within 6 hours of elution to minimize radiolytic degradation. Assess molybdenum-99 breakthrough before administration; limit is <0.15 microcurie per millicurie Tc-99m. Thyroid uptake blockers (e.g., potassium perchlorate) are recommended before brain or thyroid imaging to reduce radiation dose to thyroid. Reconstitute kits with Tc-99m pertechnetate within 1 hour of elution for optimal labeling efficiency. |
| Patient Advice | This medication is a radioactive diagnostic agent used to help visualize certain organs or tissues during imaging scans. · You will receive this injection intravenously or via other routes as determined by your healthcare provider. · Inform your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding, as radiation exposure may pose risks. · Drink plenty of fluids before and after the scan to help eliminate the radioactive material from your body. · No special dietary restrictions are required, but follow any specific instructions from your healthcare team. · The amount of radiation exposure is low and generally considered safe for diagnostic purposes. · Report any allergic reactions (rash, itching, difficulty breathing) immediately to your healthcare provider. |